Skip to main content

Table 3 Causes of morbidity in the patient group

From: Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial

Variable Standard treatment (n = 250) Intensive treatment (n = 254) P value†
Length of stay in ICU (days)    
Median (Interquartile range) 6 (3 to 11) 6 (3 to 12) 0.351
Duration of ventilatory support (days)    
Median (Interquartile range) 5 (2 to 9) 6 (2 to 10) 0.857
Ventilatory support (%) 238 (95.2) 238 (93.7) 0.476
Dopamine (%) 190 (76) 182 (71.7)  
Dosage (μg/kg/minute) *‡ 14.45 ± 8.97 14.85 ± 8.99 0.366
Norepinephrine (%) 68 (27.2) 55 (21.7)  
Dosages (μg/kg/minute) *‡ 0.36 ± 0.77 0.36 ± 0.56 0.993
Epinephrine (%) 44 (17.6) 46 (18.1)  
Dosages (μg/kg/minute) *‡ 0.34 ± 0.40 0.31 ± 0.59 0.613
Dobutamine (%) 9 (3.6) 14 (5.5)  
Dosages (μg/kg/minute) *‡ 4.97 ± 2.43 8.43 ± 6.48 0.060
Swan Ganz (%) 28 (11.2) 30 (11.8) 0.800
Renal impairment (%) § 25 (10) 32 (12.6) 0.357
Renal-replacement therapy (%) 33 (13) 27 (10.8) 0.447
Hydrocortisone (%) 66 (26.4) 67 (26.3) 0.996
Ventilator associated pneumonia (%) 55 (22) 43 (16.9) 0.15
Catheter-related infection (%) 9 (3.6) 6 (2.4) 0.414
Urinary infections (%) 11 (4.4) 13 (5.1) 0.705
Primary bacteraemia (%) 8 (3.2) 7 (2.8) 0.769
Treatment with antibiotics for ≥ 8 days (%) 183 (73.2) 186(73.2) 0.994
Red-cell transfusions    
   Patients requiring transfusions (%) 91 (36) 99 (39) 0.551
   No. of transfusions/patients* 6 ± 5.5 4.9 ± 4.1 0.412
  1. * Values presented as mean ± SD.
  2. † P values were determined wit the use of Student's t-test, the chi-square test or Fischer test as appropriate.
  3. ‡ Maximal dosage per day
  4. §Renal impairment: peak plasma creatinine > 2.5 mg/dl, Peak plasma urea nitrogen > 60 mg/dl, dialysis or continuous venovenous haemofiltration.